REGENERON PHARMACEUTICALS, INC. — Director's Dealing 2021

Dec 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS, INC. (REGN)
CIK: 0000872589
Period of Report: 2021-12-22

Reporting Person: YANCOPOULOS GEORGE (Director, President and Chief Scientific)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-22	Common Stock	M	239063	$179.13	Acquired	1126546	Direct
2021-12-22	Common Stock	F	159915	$610.04	Disposed	966631	Direct
2021-12-22	Common Stock	M	203204	$270.43	Acquired	1169835	Direct
2021-12-22	Common Stock	F	150182	$610.04	Disposed	1019653	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-22	Non-Qualified Stock Option (right to buy)	$179.13	M	239063	Disposed	2022-12-14	Common Stock (239063)	Direct
2021-12-22	Non-Qualified Stock Option (right to buy)	$270.43	M	203204	Disposed	2023-12-13	Common Stock (203204)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	5848	Indirect
Common Stock	213693	Indirect

Footnotes

F1: As investment trustee of trusts for the benefit of the reporting person's children.

F2: The stock option award vests in four equal annual installments, commencing one year after the date of grant.